The Role of OX40 (CD134) in T-Cell Memory Generation

  • Andrew D. WeinbergEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 684)


Memory T-cell generation is limited by activation-induced cell death during the effector T-cell stage. Cell surface proteins are known to transmit signals that either accentuate or limit T-cell death after activation. This chapter will focus on the TNF-receptor family member OX40, which is expressed on effector T cells and when engaged greatly enhances survival of T cells leading to increased memory T-cell generation. Targeting OX40 in vivo can alter the fate of T-cell survival. Enhancing OX40 signaling during Ag priming through agonists increases memory T-cell development, while blocking OX40 signaling decreases the memory T-cell pool. These two opposing outcomes provide therapeutic tools for blocking inflammation in autoimmune conditions and enhancing immunity in hosts harboring cancer or chronic pathogens. OX40 agonists and antagonists are in the first stages of human clinical trials and their therapeutic potential will soon be realized.


West Nile Virus Human Airway Smooth Muscle OX40 Ligand Innate Cytokine OX40 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dutton RW, Bradley LM, Swain SL. T-cell memory. Annu Rev Immunol 1998; 16:201–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007; 27(5):415–36.PubMedGoogle Scholar
  3. 3.
    Maxwell JR, Weinberg A, Prell RA et al. Danger and OX40 receptor signaling synergize to enhance memory T-cell survival by inhibiting peripheral deletion. J Immunol 2000; 164(1):107–12.PubMedGoogle Scholar
  4. 4.
    Evans DE, Prell RA, Thalhofer CJ et al. Engagement of OX40 enhances antigen-specific CD4(+) T-cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol 2001; 167(12):6804–11.PubMedGoogle Scholar
  5. 5.
    Ruby CE, Redmond WL, Haley D et al. Anti-OX40 stimulation in vivo enhances CD8(+) memory T-cell survival and significantly increases recall responses. Eur J Immunol 2007; 37(1):157–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Pippig SD, Pena-Rossi C, Long J et al. Robust B-cell immunity but impaired T-cell proliferation in the absence of CD134 (OX40). J Immunol 1999; 163(12):6520–9.PubMedGoogle Scholar
  7. 7.
    Rogers PR, Song J, Gramaglia I et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T-cells. Immunity 2001; 15(3):445–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Baum PR, Gayle RB 3rd, Ramsdell F et al. Molecular characterization of murine and human OX40/ OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J 1994; 13(17):3992–4001.PubMedGoogle Scholar
  9. 9.
    Paterson DJ, Jefferies WA, Green JR et al. Antigens of activated rat T-lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987; 24(12):1281–90.CrossRefPubMedGoogle Scholar
  10. 10.
    Takeda I, Ine S, Killeen N et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T-cells. J Immunol 2004; 172(6):3580–9.PubMedGoogle Scholar
  11. 11.
    Gramaglia I, Weinberg AD, Lemon M et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T-cell responses. J Immunol 1998; 161(12):6510–7.PubMedGoogle Scholar
  12. 12.
    Weinberg AD, Celnik B, Vainiene M et al. The effect of TCR V beta 8 peptide protection and therapy on T-cell populations isolated from the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis. J Neuroimmunol 1994; 49(1–2):161–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Buenafe AC, Weinberg AD, Culbertson NE et al. V beta CDR3 motifs associated with BP recognition are enriched in OX-40 + spinal cord T-cells of Lewis rats with EAE. J Neurosci Res 1996; 44(6):562–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164(4):2160–9.PubMedGoogle Scholar
  15. 15.
    Weinberg AD, Bourdette DN, Sullivan TJ et al. Selective depletion of myelin-reactive T-cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996; 2(2):183–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Weinberg AD. OX40: targeted immunotherapy—implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 2002; 23(2):102–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Ramstad T, Lawnicki L, Vetto J et al. Immunohistochemical analysis of primary breast tumors and tumor-draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg 2000; 179(5):400–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Vetto JT, Lum S, Morris A et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg 1997; 174(3):258–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Martin PJ, Ledbetter JA, Morishita Y et al. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T-lymphocytes. J Immunol 1986; 136(9):3282–7.PubMedGoogle Scholar
  20. 20.
    Jenkins MK, Mueller D, Schwartz RH et al. Induction and maintenance of anergy in mature T-cells. Adv Exp Med Biol 1991; 292:167–76.PubMedGoogle Scholar
  21. 21.
    Harding FA, McArthur JG, Gross JA et al. CD28-mediated signalling costimulates murine T-cells and prevents induction of anergy in T-cell clones. Nature 1992; 356(6370):607–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Kaleeba JA, Offner H, Vandenbark AA et al. The OX-40 receptor provides a potent costimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T-cells. Int Immunol 1998; 10(4):453–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T-cell costimulation. Annu Rev Immunol 1996; 14:233-58. 24._Weinberg AD, Vella AT, Croft M. OX-40: life beyond the effector T-cell stage. Semin Immunol 1998; 10(6):471–80.CrossRefGoogle Scholar
  24. 25.
    Stuber E, Neurath M, Calderhead D et al. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B-cells. Immunity 1995; 2(5):507–21.CrossRefPubMedGoogle Scholar
  25. 26.
    Stuber E, Strober W. The T-cell-B-cell interaction via OX40-OX40L is necessary for the T-cell-dependent humoral immune response. J Exp Med 1996; 183(3):979–89.CrossRefPubMedGoogle Scholar
  26. 27.
    Murata K, Nose M, Ndhlovu LC et al. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol 2002; 169(8):4628–36.PubMedGoogle Scholar
  27. 28.
    Miura S, Ohtani K, Numata N et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol Cell Biol 1991; 11(3):1313–25.PubMedGoogle Scholar
  28. 29.
    Godfrey WR, Fagnoni FF, Harara MA et al. Identification of a human OX-40 ligand, a costimulator of CD4+ T-cells with homology to tumor necrosis factor. J Exp Med 1994; 180(2):757–62.CrossRefPubMedGoogle Scholar
  29. 30.
    Imura A, Hori T, Imada K et al. The human OX40/gp34 system directly mediates adhesion of activated T-cells to vascular endothelial cells. J Exp Med 1996; 183(5):2185–95.CrossRefPubMedGoogle Scholar
  30. 31.
    Calderhead DM, Buhlmann JE, van den Eertwegh AJ et al. Cloning of mouse Ox40: a T-cell activation marker that may mediate T-B-cell interactions. J Immunol 1993; 151(10):5261–71.PubMedGoogle Scholar
  31. 32.
    Ohshima Y, Tanaka Y, Tozawa H et al. Expression and function of OX40 ligand on human dendritic cells. J Immunol 1997; 159(8):3838–48.PubMedGoogle Scholar
  32. 33.
    Sato T, Ishii N, Murata K et al. Consequences of OX40-OX40 ligand interactions in langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice. Eur J Immunol 2002; 32(11):3326–35.CrossRefPubMedGoogle Scholar
  33. 34.
    Zingoni A, Sornasse T, Cocks BG et al. Cross-talk between activated human NK cells and CD4+ T-cells via OX40-OX40 ligand interactions. J Immunol 2004; 173(6):3716–24.PubMedGoogle Scholar
  34. 35.
    Akiba H, Oshima H, Takeda K et al. CD28-independent costimulation of T-cells by OX40 ligand and CD70 on activated B-cells. J Immunol 1999; 162(12):7058–66.PubMedGoogle Scholar
  35. 36.
    Burgess JK, Carlin S, Pack RA et al. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J Allergy Clin Immunol 2004; 113(4):683–9.CrossRefPubMedGoogle Scholar
  36. 37.
    Weinberg AD, Wegmann KW, Funatake C et al. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T-cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162(3):1818–26.PubMedGoogle Scholar
  37. 38.
    Kim MY, Gaspal FM, Wiggett HE et al. CD4(+)CD3(−) accessory cells costimulate primed CD4 T-cells through OX40 and CD30 at sites where T-cells collaborate with B-cells. Immunity 2003; 18(5):643–54.CrossRefPubMedGoogle Scholar
  38. 39.
    Brocker T, Gulbranson-Judge A, Flynn S et al. CD4 T-cell traffic control: in vivo evidence that ligation of OX40 on CD4 T-cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T-cells in B follicles. Eur J Immunol 1999; 29(5):1610–6.CrossRefPubMedGoogle Scholar
  39. 40.
    Soroosh P, Ine S, Sugamura K et al. OX40-OX40 ligand interaction through T-cell-T-cell contact contributes to CD4 T-cell longevity. J Immunol 2006; 176(10):5975–87.PubMedGoogle Scholar
  40. 41.
    Murata K, Ishii N, Takano H et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000; 191(2):365–74.CrossRefPubMedGoogle Scholar
  41. 42.
    Kopf M, Ruedl C, Schmitz N et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B-cell and CTL Responses after virus infection. Immunity 1999; 11(6):699–708.CrossRefPubMedGoogle Scholar
  42. 43.
    Gramaglia I, Jember A, Pippig SD et al. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165(6):3043–50.PubMedGoogle Scholar
  43. 44.
    Jember AG, Zuberi R, Liu FT et al. Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40. J Exp Med 2001; 193(3):387–92.CrossRefPubMedGoogle Scholar
  44. 45.
    Salek-Ardakani S, Song J, Halteman BS et al. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J Exp Med 2003; 198(2):315–24.CrossRefPubMedGoogle Scholar
  45. 46.
    Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2(4):251–62.CrossRefPubMedGoogle Scholar
  46. 47.
    Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infection. J Virol 2004; 78(11):5535–45.CrossRefPubMedGoogle Scholar
  47. 48.
    Wherry EJ, Teichgraber V, Becker TC et al. Lineage relationship and protective immunity of memory CD8 T-cell subsets. Nat Immunol 2003; 4(3):225–34.CrossRefPubMedGoogle Scholar
  48. 49.
    Soroosh P, Ine S, Sugamura K et al. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T-cells. J Immunol 2007; 179(8):5014–23.PubMedGoogle Scholar
  49. 50.
    Song A, Tang X, Harms KM et al. OX40 and Bcl-xL promote the persistence of CD8 T-Cells to recall tumor-associated antigen. J Immunol 2005; 175(6):3534–41.PubMedGoogle Scholar
  50. 51.
    Hendriks J, Xiao Y, Rossen JW et al. During viral infection of the respiratory tract, CD27, 4-1BB and OX40 collectively determine formation of CD8+ memory T-cells and their capacity for secondary expansion. J Immunol 2005; 175(3):1665–76.PubMedGoogle Scholar
  51. 52.
    Melero I, Hervas-Stubbs S, Glennie M et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7(2):95–106.CrossRefPubMedGoogle Scholar
  52. 53.
    Prell RA, Evans DE, Thalhofer C et al. OX40-mediated memory T-cell generation is TNF receptor-associated factor 2 dependent. J Immunol 2003; 171(11):5997–6005.PubMedGoogle Scholar
  53. 54.
    Ruby CE, Montler R, Zheng R et al. IL-12 is required for anti-OX40-mediated CD4 T-cell survival. J Immunol 2008; 180(4):2140–8.PubMedGoogle Scholar
  54. 55.
    Redmond WL, Gough MJ, Charbonneau B et al. Defects in the Acquisition of CD8 T-Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist. J Immunol 2007; 179(11):7244–53.PubMedGoogle Scholar
  55. 56.
    Baumann R, Yousefi S, Simon D et al. Functional expression of CD134 by neutrophils. Eur J Immunol 2004; 34(8):2268–75.CrossRefPubMedGoogle Scholar
  56. 57.
    Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat Rev Immunol 2004; 4(6):420–31.CrossRefPubMedGoogle Scholar
  57. 58.
    Sadun RE, Hsu WE, Zhang N et al. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother 2008; 31(3):235–45.CrossRefPubMedGoogle Scholar
  58. 59.
    Kjaergaard J, Tanaka J, Kim JA et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 2000; 60(19):5514–21.PubMedGoogle Scholar
  59. 60.
    Kjaergaard J, Peng L, Cohen PA et al. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001; 167(11):6669–77.PubMedGoogle Scholar
  60. 61.
    Gri G, Gallo E, Di Carlo E et al. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-Apc signaling to boost the host T-cell antitumor response. J Immunol 2003; 170(1):99–106.PubMedGoogle Scholar
  61. 62.
    Murata S, Ladle BH, Kim PS et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T-cell tolerance to an endogenous tumor antigen. J Immunol 2006; 176(2):974–83.PubMedGoogle Scholar
  62. 63.
    Humphreys IR, de Trez C, Kinkade A et al. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J Exp Med 2007; 204(5):1217–25.CrossRefPubMedGoogle Scholar
  63. 64.
    Humphreys IR, Loewendorf A, de Trez C et al. OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T-Cells: A CD4-dependent mechanism. J Immunol 2007; 179(4):2195–202.PubMedGoogle Scholar
  64. 65.
    Humphreys IR, Edwards L, Walzl G et al. OX40 ligation on activated T-cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 2003; 170(12):6125–32.PubMedGoogle Scholar
  65. 66.
    Weinberg AD, Thalhofer C, Morris N et al. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 2006; 29(6):575–85.CrossRefPubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  1. 1.Robert W. Franz Cancer Research Center, Earle A. Chiles Research InstituteProvidence Portland Medical CenterPortlandUSA

Personalised recommendations